# Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients

> **NCT01518933** · PHASE2 · TERMINATED · sponsor: **Rottapharm** · enrollment: 20 (actual)

## Conditions studied

- Hepatitis C Virus Recurrence

## Interventions

- **DRUG:** Silibinin (Legalon-SIL)
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT01518933
- **Lead sponsor:** Rottapharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** when a blind review highlighted that at least 43% of patients had a virological response
- **Last updated:** 2015-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01518933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01518933, "Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01518933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*